Alkem Laboratories · NSE: ALKEM · BSE: 539523
Q3 FY21 results · Oct–Dec 2020
Alkem Laboratories reported revenue from operations of ₹2,318.05 crore (up 6.2% from Q3 FY20) and net profit of ₹463.85 crore (up 18.9% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,318.05 | 2,181.84 | +6.2% | 2,362.80 | −1.9% |
| Other income | 96.40 | 27.86 | +246.0% | 35.54 | +171.2% |
| Total income | 2,414.45 | 2,209.70 | +9.3% | 2,398.34 | +0.7% |
| Profit before tax | 543.44 | 404.61 | +34.3% | 547.75 | −0.8% |
| Net profit for the period | 463.85 | 389.96 | +18.9% | 481.51 | −3.7% |
| Attributable to shareholders of the company | 450.96 | 381.98 | +18.1% | 472.06 | −4.5% |
| EPS, basic (₹) | 37.72 | 31.95 | +18.1% | 39.48 | −4.5% |
| Net margin (%) | 20.0 | 17.9 | 20.4 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,778.75 | 1,596.40 | +11.4% | 1,984.10 | −10.3% |
| Other income | 72.46 | 26.75 | +170.9% | 24.84 | +191.7% |
| Total income | 1,851.21 | 1,623.15 | +14.1% | 2,008.94 | −7.9% |
| Profit before tax | 456.78 | 337.80 | +35.2% | 552.73 | −17.4% |
| Net profit for the period | 400.98 | 348.57 | +15.0% | 495.20 | −19.0% |
| EPS, basic (₹) | 33.54 | 29.15 | +15.0% | 41.42 | −19.0% |
| Net margin (%) | 22.5 | 21.8 | 25.0 |
Consolidated
- Filed with BSE
- 05 Feb 2021, 17:16 IST
- Board meeting
- 05 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Feb 2021, 17:16 IST
- Board meeting
- 05 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE